Agios Pharmaceuticals (NASDAQ:AGIO) Stock: Insider Sarah Gheuens Sells 1,489 Shares

Key Points

• Insider Sarah Gheuens sold 1,489 Agios shares at an average price of $37.53, generating $55,882.17; the transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced her holdings by 2.65%.
• Agios shares traded around $37.00, with a $2.21 billion market capitalization, while the company recently missed quarterly EPS expectations despite reporting revenue above analyst estimates.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $41.50, although ratings range from Strong Buy to Sell.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 1,489 shares of the business's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $37.53, for a total transaction of $55,882.17. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at $2,050,826.85. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $37.52, for a total transaction of $18,760.00.
• On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $30.48, for a total value of $914,400.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO traded down $0.19 during midday trading on Friday, hitting $37.00. The stock had a trading volume of 920,048 shares, compared to its average volume of 1,059,158. The company has a 50 day simple moving average of $33.34 and a two-hundred day simple moving average of $32.76. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00. The firm has a market cap of $2.21 billion, a price-to-earnings ratio of -5.28 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. The firm had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million. Analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 EPS for the current fiscal year.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Inspire Investing LLC raised its stake in Agios Pharmaceuticals by 4.7% during the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company's stock worth $636,000 after buying an additional 861 shares during the period. Assenagon Asset Management S.A. increased its holdings in Agios Pharmaceuticals by 1,714.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company's stock worth $62,723,000 after purchasing an additional 1,782,457 shares in the last quarter. Tidal Investments LLC raised its stake in shares of Agios Pharmaceuticals by 12.0% in the second quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company's stock worth $597,000 after purchasing an additional 1,724 shares during the last quarter. Engineers Gate Manager LP raised its stake in shares of Agios Pharmaceuticals by 86.4% in the second quarter. Engineers Gate Manager LP now owns 53,912 shares of the biopharmaceutical company's stock worth $2,001,000 after purchasing an additional 24,992 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $47,000.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on AGIO shares. Royal Bank Of Canada raised their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a "sector perform" rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Citigroup raised their target price on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, July 31st. HC Wainwright increased their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Finally, Truist Financial decreased their price target on Agios Pharmaceuticals from $39.00 to $37.00 and set a "buy" rating on the stock in a research note on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $41.50.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.